Curevac Nv Stock Today
| CVAC Stock | USD 3.01 0.02 0.66% |
PerformanceWeak
| Odds Of DistressBelow Average
|
CureVac NV is trading at 3.01 as of the 17th of March 2025, a 0.66 percent down since the beginning of the trading day. The stock's open price was 3.03. CureVac NV has about a 34 percent probability of financial distress in the next few years of operation and did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 17th of December 2024 and ending today, the 17th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 14th of August 2020 | Category Healthcare | Classification Health Care |
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid . The company was founded in 2000 and is headquartered in Tbingen, Germany. Curevac NV operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 224.34 M outstanding shares of which 3.74 M shares are currently shorted by private and institutional investors with about 6.1 trading days to cover. More on CureVac NV
Moving against CureVac Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
CureVac Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| MD CEO | MD MBA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsCureVac NV can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand CureVac NV's financial leverage. It provides some insight into what part of CureVac NV's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CureVac NV (CVAC) is traded on NASDAQ Exchange in USA. It is located in Friedrich-Miescher-Strasse 15, Tübingen, Germany, 72076 and employs 999 people. CureVac NV is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 675.26 M. CureVac NV conducts business under Biotechnology sector and is part of Health Care industry. The entity has 224.34 M outstanding shares of which 3.74 M shares are currently shorted by private and institutional investors with about 6.1 trading days to cover.
CureVac NV currently holds about 540.87 M in cash with (267.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.85.
Check CureVac NV Probability Of Bankruptcy
Ownership AllocationCureVac NV holds a total of 224.34 Million outstanding shares. CureVac NV retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check CureVac Ownership Details
CureVac Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Bnp Paribas Arbitrage, Sa | 2024-12-31 | 171.7 K | |
| Deutsche Bank Ag | 2024-12-31 | 169.9 K | |
| Freestone Capital Holdings, Llc | 2024-12-31 | 144.1 K | |
| Legal & General Group Plc | 2024-12-31 | 114.8 K | |
| Two Sigma Investments Llc | 2024-12-31 | 114.7 K | |
| Susquehanna International Group, Llp | 2024-12-31 | 97.9 K | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 97.3 K | |
| Pictet Asset Manangement Sa | 2024-12-31 | 95.4 K | |
| Dekabank Deutsche Girozentrale | 2024-12-31 | 85.6 K | |
| Millennium Management Llc | 2024-12-31 | 1.6 M | |
| Bill & Melinda Gates Foundation | 2024-09-30 | 1.6 M |
CureVac NV Historical Income Statement
CureVac Stock Against Markets
CureVac NV Corporate Management
| Pierre BSc | CFO MD | Profile | |
| Patrick Baumhof | Senior Technology | Profile | |
| AxelSven Malkomes | Chief Officer | Profile | |
| Ronald Plasterk | Senior Innovation | Profile | |
| Igor MSc | Chief Board | Profile | |
| Antony Blanc | Chief MD | Profile | |
| Sarah Fakih | Vice Relations | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CureVac NV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade CureVac Stock refer to our How to Trade CureVac Stock guide.You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CureVac NV. If investors know CureVac will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CureVac NV listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.51 | Revenue Per Share | Quarterly Revenue Growth 0.905 | Return On Assets | Return On Equity |
The market value of CureVac NV is measured differently than its book value, which is the value of CureVac that is recorded on the company's balance sheet. Investors also form their own opinion of CureVac NV's value that differs from its market value or its book value, called intrinsic value, which is CureVac NV's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CureVac NV's market value can be influenced by many factors that don't directly affect CureVac NV's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CureVac NV's value and its price as these two are different measures arrived at by different means. Investors typically determine if CureVac NV is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CureVac NV's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.